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Introduction. Dendritic cells (DCs) and oxLDL play an important role in the atherosclerotic process with DCs accumulating in the
plaques during plaque progression. Our aim was to investigate the role of oxLDL in the modulation of the DC homing-receptor
CCR7 and endothelial-ligand CCL21. Methods and Results. The expression of the DC homing-receptor CCR7 and its endothelial-
ligand CCL21 was examined on atherosclerotic carotic plaques of 47 patients via qRT-PCR and immunofluorescence. In vitro, we
studied the expression of CCR7 on DCs and CCL21 on human microvascular endothelial cells (HMECs) in response to oxLDL.
CCL21- and CCR7-mRNA levels were significantly downregulated in atherosclerotic plaques versus non-atherosclerotic controls
[90% for CCL21 and 81% for CCR7 (P < 0.01)]. In vitro, oxLDL reduced CCR7 mRNA levels on DCs by 30% and protein
levels by 46%. Furthermore, mRNA expression of CCL21 was significantly reduced by 50% (P < 0.05) and protein expression
by 24% in HMECs by oxLDL (P < 0.05). Conclusions. The accumulation of DCs in atherosclerotic plaques appears to be related
to a downregulation of chemokines and their ligands, which are known to regulate DC migration. oxLDL induces an in vitro
downregulation of CCR7 and CCL21, which may play a role in the reduction of DC migration from the plaques.
1. Introduction
Atherosclerosis is a dynamic inflammatory disease [1, 2] in
which autoantigenes, such as oxidized low-density protein
(oxLDL), play an essential role. Dendritic cells (DCs) are
key regulatory antigen-presenting cells (APCs) that induce
inflammatory processes. DCs can be detected in the vascular
inflammatory environment, from endothelial dysfunction to
consecutive plaque formation and rupture [3–5]. DCs are
the most potent APCs and are highly specialized to prime
naive T-cells [6]. Interestingly, mature DC-specific markers,
for example, CD83, accumulate during plaque progression.
It has been shown previously that the presence of CD83 is
more than two fold, higher in symptomatic compared to
asymptomatic patients [7].
DCs, after entering the vascular tissue, screen the envi-
ronment for potential antibodies [2]. After processing the
antigens, a maturation process is initiated and immunomod-
ulatory receptors, such as the CD83-receptor (important for
T-cell-stimulation), are upregulated [8]. In a previous study,
we found a CD83 upregulation on DCs by proatheroscle-
rotic stimuli like oxLDL and asymmetric dimethylarginine
(ADMA) [9]. Beside CD83, DC induces CCR7 expression
during maturation, which acts as a receptor for constitutively
expressed CCL21 and CCL19 [10, 11]. In analogy to DC
accumulation and maturation, activated CCR7 expressing
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T-cells are trapped especially in the plaque shoulders [12, 13]
where mature DCs are forming clusters with T cells [13].
Several studies have demonstrated the important link
between DC/T-cell recruitment and CCR7 expression [12–
14]. The increase in CCR7 receptors induces homing of
mature DCs and T-cells to the lymph nodes through CCL21/
CCL19 expressing lymph vessels [2, 11, 12].
High plasma concentrations of oxLDL and their appear-
ance in atherosclerotic lesions are of utmost importance in
the pathogenesis of atherosclerosis [15].
The present study focuses on the influence of oxLDL
on the DC-related chemokine receptors CCR7, CCL19, and
CCL21. We characterized the DC-specific chemokine-ligand
expression in human atherosclerotic carotid artery plaques.
Furthermore, we investigated the impact of oxLDL on the
DC receptor CCR7 expression and its ligands CCL-21 on
human microvascular endothelial cells (HMECs).
2. Materials and Methods
2.1. In Vivo
2.1.1. Study Population. All investigations were approved by
the institutional review board and the ethics committee of
the Ludwig-Maximilians University of Munich. Informed
consent was obtained from all patients. The investigation
conforms to the principles outlined in the declaration of
Helsinki. Between September 2006 and May 2008, carotid
endarterectomy (CEA) was performed in 47 patients. The
indications for CEA were based on carotid duplex sonog-
raphy: stenosis of the internal carotid artery of more than
70% for symptomatic patients and more than 85% for
asymptomatic patients. For comparison, we collected 10
blood samples from healthy age-matched men without
clinically manifested atherosclerosis and 14 pieces of aortic
tissue with no visible atherosclerotic lesions.
2.1.2. RNA Isolation from Atherosclerotic Plaque for Real-Time
PCR. 100 mg plaque tissue was homogenized in 1 mL QIA-
zol Lysis. 50 pg/tube RNA (PBMCs) was used. First-strand
cDNA synthesis and PCR were performed using Omniscript
from Qiagen (Hilden, Germany). The two-step quantitative
real-time PCR (rt-PCR) system was applied according to
the manufacturers’ instructions. The quantitative real-time
PCR system provides optimal performance with SYBR
Green primers (Qiagen: Hilden, Germany). Rt-PCR was
performed in the ABI PRISMTM 7700 System (Applied
Biosystems, Germany). Data analysis was performed using
the delta-delta-Ct method as described previously [16].
Primer sequences for the amplified fragments were GAPDH:
5′-CGG AGT CAA CGG ATT TGG TCG TAT-3′/5′-AGC
CTT CTC CAT GGT GGT GAA GAC-3′; CCR7: 5′-TGG
AGG CCT TTA TCA CCA TC-3′/5′-TGT AGG GCA GCT
GGA AGA CT-3′; CCL19: 5′-CTG TGA CCC AGA AAC CCA
TC-3′/5′-GCT TCA TCT TGG CTG AGG TC-3′; CCL21: 5′-
CCC AGC TAT CCT GTT CTT GC-3′/5′-TCA GTC CTC
TTG CAG CCT TT-3′; CD4: 5′-AGG AAG TGA ACC TGG
TGG TG-3′/5′-CTC AGC AGA CAC TGC CAC AT-3′.
2.1.3. Immunofluorescence Analysis of CCL21 Expression in
Human Plaque and Aortic Tissue. Frozen sections (10 μm)
were prepared from human aorta and plaque material of the
internal carotid artery. After fixation in methanol/ethanolic
acid for 1.5 min at −20◦C, the sections were washed imme-
diately 3 times for 3 min in PBS. Unspecific binding was
blocked with a 2% BSA/0.2% Tween 20 solution for 1 h
and followed by 3 washing steps in PBS. To visualize
nucleoli we used DAPI (4′, 6′Diamidino-2′phenylindole,
Merck KGaA, Germany) in a final concentration of 1 μg/mL.
After another washing step the sections were incubated with
a fluorescent labelled anti-human CCL21/6Ckine antibody
(5 μg/mL, R&D Systems, Inc., Germany).
To determine the localization of the CCL21 expressing
structure (CCL21/6Ckine antibody 5 μg/mL, R&D Systems,
Inc., Germany), the sections were also incubated with a Cy3-
labeled anti-PECAM-1 antibody (5 μg/mL, AbD Serotec,
Germany), which demarcates the endothelia cells in the ves-
sel wall. Immunofluorescence analysis of CCL21 expression
was investigated by confocal microscopy (LSM 510 META,
Zeiss, Plan-Neofluar 40x/1.30 oil objective, Germany) and
quantified by LSM Image Browser 4.2 (Zeiss, Germany).
2.1.4. Immunofluorescence Analysis of CCR-7/CD4- and CCR-
7/CD83-Coexpression in Human Plaque and Aortic Tissue.
The sections were incubated with an FITC-labelled anti-
human CCR7 antibody (1 : 100 concentration, R&D Systems,
Inc., Germany) for 1 h, followed by 3 washing steps in PBS.
The sections were incubated with an Atto594-labeled
anti-CD4 antibody (10 μg/mL, AbD Serotec, Germany) or
Atto594-labelled anti-CD83 (10 μg/mL, AbD Serotec, Ger-
many) for 1 h, which represents the T-lymphocytes (CD4) or
mature DC (CD83). The immunofluorescence analysis was
investigated by confocal microscopy (LSM 510 META, Zeiss,
Plan-Neofluar 40x/1.30 oil objective, Germany).
2.1.5. ELISA for oxLDL and CCL21. Plasma tubes were cen-
trifuged and the plasma was fractionated and frozen at
−80◦C.
oxLDL levels were examined by using a cytokine-specific
ELISA kit according to the manufacturers’ instructions (Im-
munDiagnostik, Bensheim, Germany) [17]. Before analysis,
samples were treated as described above. In brief, after
washing with wash buffer several times, standard samples
and controls were added and incubated for 4 hours at
room temperature on a horizontal mixer. Thereafter, a
washing conjugate was added and incubated for 1 h as
described before. The substrate was added and incubated
for 25 minutes in the dark. Stop-solution was added and
immediately analyzed by an ELISA-reader at 450 nm.
Detection of CCL21 in serum was also performed by
a quantitative sandwich enzyme immunoassay technique,
according to the manufacturers’ instructions (R&D Systems,
Germany).
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2.2. In Vitro
2.2.1. Generation of Monocyte-Derived Dendritic Cells (DCs).
Mononuclear cells were isolated from 100 mL of peripheral
blood of a healthy human donor by a Ficoll density gradient
according to the protocol by Boyum [18]. The purity of
the monocyte culture was enhanced up to 97% by adhesion
on γ-globulin coated plates. DCs were obtained from the
monocyte culture according to the modified protocol by
Romani et al. [19] as described in detail in our recent
publication [9, 17].
2.2.2. Endothelial Cells (ECs). All experiments were per-
formed with human microvascular endothelial cells
(HMECs-1), generously provided by the Center for Disease
Control and Prevention and the National Center for Infec-
tious Disease (Atlanta, USA). Cells were cultured in MCDB-
131 (without phenol red; cc pro, Neustadt/W., Germany)
supplemented with 10% fetal calf serum (FCS; PAA,
Pasching, Austria), 2 mM L-Glutamine (Biochrom AG,
Berlin, Germany), 1 μg/mL hydrocortisone, and 10 ng/mL
epidermal growth factor (Sigma, Taufkirchen, Germany).
The cells were used at least 10 days after thawing and for no
more than 20 passages [20].
2.2.3. LDL Oxidation. LDL (density = 1.019 to 1.063 g/mL)
was isolated from human plasma of normolipidemic healthy
volunteers by sequential ultracentrifugation as described and
stored in PBS containing 2 mmol/L EDTA. Shortly before
oxidation, the EDTA was removed from LDL by passing the
lipoprotein through a PD 10 column (Pharmacia, Austria).
LDL was oxidized in Ham’s F-10 medium by exposure to
5 μmol/L CuSO4 at 37◦C for 30 h [11, 21]. All preparations
were dialyzed before they were added to the cultured cells.
This reflects oxLDL concentrations in the plaque and has
been used in previous studies [5, 22, 23]. In addition, several
other studies have shown that an oxLDL concentration of
(10 μg/mL) is not toxic to the cultured cells [9, 24, 25]
2.2.4. Total RNA Isolation and Real-Time PCR. For isolation
of mRNA from HMECs-1 and DCs, the total RNA isolation
RNAeasy Mini Kit from Qiagen (Hilden, Germany) was used
according to the instructions provided by the manufacturer.
50 pg/tube RNA (PBMC) was used. First-strand cDNA
synthesis and PCR were performed using Omniscript from
Qiagen (Hilden, Germany). The two-step quantitative RT-
PCR system was applied according to the manufacturers’
instructions and as described above [16].
2.2.5. Flow-Cytometric Analysis of DCs. Cells were incu-
bated with antibodies according to the manufacturers’
instructions. Fixed cells were analyzed on an FACS Calibur
cytometer (Becton Dickinson). Antibodies were matched
to iso-type-controls (Mouse-γ2a-(FITC)/-γ1(PE)-Fastim-
mune; BD; USA). To verify the purity of our DC-culture,
we used CD3 (BD, USA) and CD20 (BD, USA) to rule
out a T-cell and B-cell contamination (<5%). DCs were
characterized by low CD14 expression (BD, USA) and high
expression of CD80 (BD, USA), CD86 (BD, USA), and HLA-
DR (BD, USA), as described previously [26].
At day five, we incubated the DCs with oxLDL (10 μg/
mL) for 24 hours. Expression analysis of the chemok-ine
receptor CCR7 (R&D, USA) and CD83 (BioLegend, USA) on
human DCs were performed using flow-cytometer analysis
[16, 17].
2.2.6. Immunofluorescence of CCL21 on HMECs-1. HMECs-
1 were cultivated on chamber slides and stimulated with
10 μg/mL oxLDL for 48 h. The monoclonal antibody for
CCL21/6Ckine (R&D, USA) was labeled with Alexa 488
using the Alexa Fluor Protein Labeling Kit (Invitrogen, life
technologies, USA) according to the manufacturers’ instruc-
tions. HMECs-1 were incubated with the labeled antibody
(concentration 1 : 20) for 30 minutes. Thereafter, Vybrant
DiD (Invitrogen, life technologies, USA) was used as a
marker of the plasma membrane. CCL21-labeled HMECs-
1 were investigated by confocal microscopy (Zeiss LSM
510 Meta, Plan-Apochromat 63x/1.40 oil objective) and
quantified by LSM Image Browser 4.2 (Zeiss, Germany).
2.2.7. Statistical Analysis. Data is presented as ± standard-
deviation of the mean (SDM). The Kolmogorov-Smirnov
test was used to determine whether or not the data was
normally distributed. If the data was normally distributed,
the unpaired t-test was used to compare the two groups. Data
that was not normally distributed was compared using the
Wilcoxon signed Rank Test. Differences between means were
considered significant with P < 0.05 and highly significant
with P < 0.01. All in-vitro experiments were repeated at least
eight times with different cells and lipoprotein preparations.
SPSS (version 16, Leibniz Rechenzentrum Munich) was used
for statistical analysis.
3. Results and Discussion
3.1. In Vivo
3.1.1. Study Population. Carotid plaque tissue and blood sam-
ples were collected from 47 patients undergoing CEA, of
which 77% were male and, on average, 70 ± 8 years of age.
66% had asymptomatic disease, whereas and the rest showed
cerebral ischemic complications. The different risk profiles
and medication are summarized in Table 1.
Serum for the PBMCs in the control group was collected
from 10 healthy age-matched patients. 60% were of male
gender with an average age of 68±4 years. None had cerebral
ischemic complications or clinical manifest atherosclerosis.
Concerning the risk-profile, 20% had insulin-dependent
diabetes mellitus, 80% hypertension, and 10% were smokers.
Concerning the medication, 10% took thrombocyte aggre-
gation inhibitors, 80% statins, and 60% had a β-blocker
(Table 1).
Aortic tissue in the control group was collected from
14 patients who underwent valve replacement and had no
sign of aortic atherosclerosis. 71% were of male gender
with an average age of 64 ± 5 years. 14% had a cerebral
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Table 1: Clinical characteristics of the patients and controls. Clin-
ical characteristics including age, sex, cardiovascular risk factors,
relevant medication, oxLDL and CCL21 of patients who received
CEA and healthy controls without clinical history of manifest
atherosclerosis.
CEA-patients healthy controls
(n = 47) (n = 10)
Age (years) 70± 8 68± 4
men % (n) 77 (36) 60 (6)
TIA/CI % (n) 32 (15) 0 (0)
ID DM % (n) 26 (12) 20 (2)
Hypertension % (n) 91.5 (43) 80 (8)
Hyperlipidemia % (n) 85 (40) 80 (8)
Nicotine abusus % (n) 38 (18) 10 (1)
ASS/Clopidogrel % (n) 91.5 (43) 10 (1)
β-blocker % (n) 60 (28) 60 (6)
Statins % (n) 79 (37) 80 (8)
oxLDL (ng/mL) 207.3± 240.2 99.4± 20.3
CCL21 (pg/mL) 1335.1± 771.5 961.2± 210.9
ischemic event. Concerning the risk profile, 28% had
insulin-dependent diabetes mellitus, 85% hypertension, and
35% were smokers. With respect to medication, 43% took
thrombocyte aggregation inhibitors, 78% statins, and 43%
had a β-blocker.
3.1.2. CCL21/CCL19 and CD83/CCR7 and CD4 mRNA
Analysis of the Atherosclerotic Plaque. In line with previous
investigations, we detected that the median CD83 mRNA
levels in plaque tissue from CEA-group were nearly twice as
high as in healthy aortic tissue (P < 0.01), demonstrating
the augmented presence of mature DCs in the atherosclerotic
tissue [7, 27, 28]. In a subgroup analysis, we further found
that CD83 levels in men were significantly higher (+120%;
P < 0.05) compared to women. CD4 mRNA levels were
even 23 ± 11 fold higher in healthy aortic tissue (P < 0.01;
data not shown).
CCR7, normally coexpressed on mature DCs and T-cells,
was 81% lower in the plaque compared to compared to
healthy aortic tissue (P < 0.01) without any gender specific
differences.
Further analysis of CCL19 revealed that its transcripts
were downregulated by 99% (P < 0.01). CCL21 was found
90% lower in the plaque (P < 0.01) compared to healthy
aortic tissue (Figure 1).
Furthermore CCL21 was also found lower in the symp-
tomatic patients (58%; P < 0.05) compared to asymptomatic
patients from the CEA group.
3.1.3. Immunofluorescence Analysis of CCL21 Expression in
Human Plaque and Aortic Tissue. To confirm the PCR results
on the protein level, we performed a semiquantitative im-
munofluorescence analysis on histological slides of human
aortic and plaque tissue.
To analyze the location of CCL21 expressing cells, we
stained the endothelial cells (α-PECAM-1-Cy3) in the aortic
tissue section. This revealed a colocalization of the CCL21
and the vascular wall of the vasa vasorum (Figure 2(a)).
In every single healthy aortic tissue slide (n = 6), we
could detect higher CCL21 expression via an increased fluo-
rescence signal signal from the binding fluorescent antibody
than in the plaque tissue (n = 15). An example is shown
(n = 15; in Figure 2(b)).
3.1.4. Immunofluorescence Analysis of CCR-7/CD4 and CCR-
7/CD83 Coexpression in Human Plaque and Aortic Tissue.
To further investigate differences of the CCR7 level on T-
lymphocytes (CD4 positive) and mature DC (CD83 positive)
in human tissue, immunofluorescence analysis was used.
By double staining, we could detect a decreased signal
of CCR7 on CD4-positive cells within the plaque tissue
(Figure 2(c); lower panel) compared with control aortic
tissue (Figure 2(c); upper panel). Also, CD83-expressing
cells within the plaque show a decreased CCR7 signal
(Figure 2(d); lower panel) compared to the aortic tissue
which correlates with the PCR results.
3.1.5. Circulating oxLDL and CCL21 Concentrations. For
oxLDL, we found a 52.1% (P < 0.05) higher concentration
in the plaque group compared to the control group (Table 1).
oxLDL serum concentrations showed no correlation with
CCL21/CCL19 or CCR7 expressions in plaques (Table 1).
For CCL21, we found a 28% (P < 0.01) higher serum
concentration in the CEA group compared to the controls
(Table 1).
3.2. In Vitro Cell Experiments
3.2.1. CCR7 and CCL21/CCL19 Expression in DCs and
HMECs-1. After stimulation with oxLDL, we found a reduc-
tion of the mRNA levels of CCR7 (DCs) by 30% using RT-
PCR (n = 8; P < 0.05). This correlated with a reduction
in protein expression by 46% (n = 8; 25.7 ± 1.06% versus
control 47.6 ± 19.3% positive cells; P < 0.05; Figure 3).
In contrast, protein expression of CD83 was significantly
upregulated by 10 μg/mL oxLDL, as shown in Figure 3 (60%,
46.9±11.3 versus control 29.3±17.7% positive cells; P < 0.05;
Figure 2) by 10 μg/mL oxLDL (Figure 3).
For HMECs-1, stimulation with oxLDL led to a signif-
icant reduction of CCL21 mRNA expression (50%; ΔΔct =
0.5; P < 0.05, Figure 4(a)). These results correspond with the
results of the immunofluorescence analysis, where we found
a 24% down-regulation of CCL21 receptor expression (n = 9;
34.00 ± 8.53 versus control 44.54 ± 6.23 intensity/mm2; P <
0.05; Figures 4(b) and 4(c). oxLDL had no significant impact
on protein or mRNA expression of CCL19 (Figure 4(a)).
4. Discussion
The main findings obtained from our study are (1) The DC-
chemokine receptor CCR7 and its ligands CCL21/CCL19
are significantly downregulated in atherosclerotic plaques;







































CCL19 CCL21 CCR7 CD83
Figure 1: mRNA expression of CCL21/19, CCR7, and CD83 in vascular plaques compared to aortic tissue without plaque detection. In vivo
changes (relative fold increases) in mRNA expression of CCL19, CCL21, CCR7, and CD83 in carotid plaques compared to healthy aortic
material. ∗P < 0.05, ∗∗P < 0.01, (n = 47) versus aortic tissue (n = 14).
Dapi CCL21 Merge
Pecam-1 CCL21 Merge
10 µm 10 µm 10 µm
50 µm 50 µm 50 µm
(a) Analysis of the CCL21, expressing structures in human aortic tissue
Lumen
Lumen
50 µm 50 µm
Aorta Carotis
(b) Localisation of CCL21, positive cells in aortic tissue and carotis
plaque
Figure 2: Continued.
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(c) Analysis of the coexpression of CCR7 and CD4
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(d) Analysis of the coexpression of CCR7 and CD83
Figure 2: Protein expression of CCL21 and CCR7 on carotid plaque and aortic tissue. (a) Analysis of the CCL21 expressing structures in
human aortic tissue. In the upper part the blue staining represents the cell nuclei (DAPI) and the red staining represents CCL21, positive
structures (α-CCL21/6Ckine-Alexa488, pseudocolored). Scale bar 10 μm. To examine the vessel wall as CCL21 expressing structures (lower
part) in human aorta tissue endothelial cells were stained with a PECAM-1 antibody (green, α-PECAM-1-Cy3, pseudocolored). The red
staining represents CCL21 (α-CCL21/6Ckine-Atto594). The merged picture shows a co-localization of CCL21 and PECAM-1 in the vessel
wall of the human aorta. Scale bar 50 μm. (b) The representative pictures show differences in the expression level of CCL21 (red, α-
CCL21/6Ckine-Atto594) in aorta and carotid plaque tissue. A decreased CCL21-protein expression in carotid plaque compared to aorta
tissue was shown by immunofluorescence microscopy. CCL21 is primarily expressed by the vasa vasorum of the vessel. Scale bar 50 μm. (c)
A decreased CCR7 expression (green, α-CCR7-FITC) on CD4 positive cells (red, α-CD4-Atto594) was detectable in plaque tissue compared
to aorta tissue. Arrows indicate the cells. Scale bar 20 μm. (d) Also a decreased CCR7 expression (green, α-CCR7-FITC) on CD83, positive
cells (red, α-CD83-Atto5994) in aorta and plaque tissue is shown in the representative pictures. Arrows indicate the cells. Scale bar 20 μm.











































Figure 3: Protein expression of CD83 and CCR7 on DCs after
stimulation with oxLDL. An increase of the expression of CD83 and
a decrease of the expression of CCR7on DCs after stimulation with
oxLDL (10 μg/mL) was observed. Positive cells were measured by
flow cytometry and the percent (%) changes were plotted in the
figure. ∗P < 0.05, (n = 8) versus unstimulated controls.
(2) Circulating CCL21 levels are upregulated in serum from
atherosclerotic patients; (3) oxLDL impairs CCR7 expression
in DCs and CCL21 expression in microvascular ECs.
Our data support the concept that modulation of
chemokine receptors (mediated, e.g., by oxLDL) in the
plaque may trigger retention of DCs, thereby impeding the
vascular innate and adaptive immunity [29, 30]. Accordingly,
Angeli et al. found that oxLDL and other lipid mediators
are jointly responsible for trapping of DCs in the vascular
wall [29]. In our in vivo study, oxLDL serum concentra-
tions showed no correlation with CCL21/CCL19 or CCR7
expression in plaques. However, CCR7 and CCL21/CCL19
were downregulated in atherosclerotic plaques compared to
nonatherosclerotic aortic tissue. This discrepancy may be
explained by the fact that oxLDL is unstable in serum but
accumulates in the subintimal space over time. Hereby, it
reaches much 70 fold higher subintimal concentrations as
compared to serum levels [31]. This fact especially appeases
to monocytes rich plaques [31].
We found CCR7 expression to be downregulated after
24 hours of stimulation with oxLDL. Alongside, CCL21 was
downregulated on HMECs-1 after incubation with oxLDL,
in a concentration which predominates in atherosclerotic
plaques. Trogan et al. previously demonstrated that phases
of hyperlipidemia severely reduce CCR7 mRNA and the
corresponding protein levels in an ApoE−/−-mice model.
CCR7 increased in the presence of normolipidemia. In their
work, CCR7 expression was found to be essential for the
migration of DCs from atherosclerotic plaque. In atheroscle-
rotic plaques of ApoE−/−-mice, CCR7 receptor expression
was reduced. When transferred to wild-type mice, this
process was accompanied by an upregulation of CCR7 itself
[32].
Under a high-dose statin therapy, Damas et al. found
a significant decrease in CCL19 and CCL21 levels in serum
[2]. Our data support this observation, showing reduced
CCL21 serum protein expression in the control group,
characterized by low oxLDL levels. The difference in controls
was evident despite a low-dose statin therapy.
Our results suggest that DC maturation is triggered by
increased oxLDL deposits in the subintimal space. At the
same time DCs, and even T-cells do not seem to express
enough CCR7 receptors in order to migrate. As a con-
sequence, oxLDL, DCs and T-cells appear to accumulate,
thereby enhancing plaque inflammation processes and pos-
sibly plaque rupture.
These results complement the former findings that
oxLDL increased the adhesion and promotes the matura-
tion and differentiation of DCs from monocytes [9, 26].
Furthermore, oxLDL supports the building of foam-cell
accumulations and also directly induces chemotaxis of
immune cells like T-cells via upregulation of endothelial
adhesion molecules [9]. Keeping in mind that DCs are
responsible for priming naive T-cells to oxLDL-specific T-
cells [9, 33], the interaction of oxLDL and DCs must be taken
into account as a key factor for the induction and progression
of atherosclerosis.
oxLDL not only seems to have an influence on the expres-
sion of CCR7, but also to induce downregulation of CCL21
on ECs in vitro as well as decreased expression of CCL21 and
CCL19 in the plaque. Comparing CCL19 with CCL21, the
latter appears to be affected more directly by local plaque
homing factors. In plaque versus normal aortic tissue, we
found a much higher response to CCL21 on ECs as opposed
to CCL19. Typically, the expression of CCL21 on ECs is
higher than CCL19 [11], since CCL21 has a C-terminus
indicating a strong affinity to glycosaminoglycan. This is
crucial for effective presentation of CCL21 on ECs [11, 34].
In contrast to our study, other investigators demon-
strated an upregulation of CCL21/CCL19 in carotid plaques
[7]. In previous studies, 2–4 coronary or renal vessels from
autopsy material were taken as controls. To overcome these
limitations, we used 14 age-matched healthy aortic tissue
samples taken from valve operations serving as controls,
which were immediately frozen after their operative prepara-
tion, similar to the procedures of carotid tissue preparation.
Autolysis and coincidence caused by the small number of
controls were therefore ruled out in our experimental setting.
A further aspect which points against the renal vessels as
controls is the fact, that the vascular-associated lymphoid
tissue (including DC and T-cells) has been characterized
in human large arteries, including the aorta, carotid, and
coronary arteries [35, 36] but not in renal vessels.
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(c) Quantification of the fluorescence intensity
Figure 4: mRNA expression of CCL21/19 and protein expression of CCL21 on HMECs-1 after stimulation with oxLDL. (a) Fold increase in
mRNA expression levels of CCL21/19 in human microvascular endothelial cells after 48 h of stimulation with oxLDL (10 μg/mL) analyzed
by real-time PCR. ∗P < 0.05, (n = 9) versus unstimulated controls. (b) Corresponding protein expression of CCL21 measured by
immunofluorescence analysis. The green staining represents CCL21 positive structures (α-CCL21/6Ckine-Alexa488), red represents the
plasma membrane (Vybrand DiD). Scale bar 10 μm. (c) The fluorescence intensity was quantified showing a significant change for oxLDL.
∗P < 0.05, (n = 8) versus unstimulated control.
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5. Conclusions
In summary, our results suggest that alterations in the vascu-
lar chemokine profile may be responsible for accumulation
of mature DCs in plaque, which potentially enhance the risk
for plaque rupture. It may be argued that inhibiting DC
migration leads to a less robust immune response. Indeed,
altered priming can be expected in the presence of impaired
DC migration. However, if migration is blocked and matura-
tion enabled, the consequence of trapping mature DCs in the
direct atherogenic vicinity may induce plaque formation and
progression or even rupture. Suppression of DC migration
and maturation may, therefore, prove a promising future
therapeutic target to prevent plaque instability and rupture.
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